NEW YORK, May 7 (GenomeWeb News) - Caliper Life Sciences reported three times increased revenues for the first quarter today, while losses remained stable.
Revenues were $16.9 million, up from $5.6 million during the same period last year. This increase was mainly due to revenues from Zymark, which Caliper acquired last July.
Research and development costs decreased to $6.5 million, from $9.4 million during the same quarter in 2003.
Caliper's net loss for the quarter was $10 million, or $.35 per share, compared to $10 million, or $.4 per share, during the year-ago period.
At the end of March, Caliper had $5.6 million in cash and cash equivalents, and $50.3 million in marketable securities.